Insider Selling: Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Director Sells 4,557 Shares of Stock

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) Director Jeffrey Allen Bailey sold 4,557 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $8.43, for a total value of $38,415.51. Following the transaction, the director now directly owns 13,356 shares in the company, valued at approximately $112,591.08. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Aurinia Pharmaceuticals Stock Down 1.3 %

Shares of NASDAQ:AUPH opened at $8.38 on Wednesday. Aurinia Pharmaceuticals Inc. has a one year low of $4.71 and a one year high of $10.05. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. The company has a market cap of $1.20 billion, a price-to-earnings ratio of -55.87 and a beta of 1.45. The firm has a fifty day moving average price of $7.16 and a two-hundred day moving average price of $6.15.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Several hedge funds have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. increased its holdings in Aurinia Pharmaceuticals by 13.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 744,050 shares of the biotechnology company’s stock valued at $5,454,000 after acquiring an additional 89,940 shares during the last quarter. Intech Investment Management LLC acquired a new position in Aurinia Pharmaceuticals during the 3rd quarter valued at approximately $262,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Aurinia Pharmaceuticals during the third quarter worth $3,330,000. Segall Bryant & Hamill LLC lifted its holdings in Aurinia Pharmaceuticals by 1.6% during the third quarter. Segall Bryant & Hamill LLC now owns 562,775 shares of the biotechnology company’s stock valued at $4,125,000 after purchasing an additional 9,031 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Aurinia Pharmaceuticals by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 27,502 shares of the biotechnology company’s stock worth $202,000 after buying an additional 10,700 shares in the last quarter. Institutional investors own 36.83% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on AUPH. HC Wainwright reissued a “buy” rating and issued a $13.00 target price on shares of Aurinia Pharmaceuticals in a report on Friday, September 6th. StockNews.com upgraded Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, November 8th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $10.00 price target on shares of Aurinia Pharmaceuticals in a report on Monday, September 16th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $10.00.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.